Given the success of MEK inhibition for the control of plexiform neurofibromas and that many MPNST arise from within existing plexiform neurofibromas or ANNUBPs, it would seem likely that patients with MPNST could already be undergoing treatment with a MEK inhibitor. The gene discussed is MAP2K7; the disease is neurofibroma.